SWM
SWM”), and the Directors of Scapa Group plc (“
Scapa”) are pleased to announce that they have reached agreement on the terms of a recommended cash offer by SWM Bidco for the acquisition of the entire issued and to be issued ordinary share capital of Scapa (the “
Offer”). The Offer is intended to be effected by means of a scheme of arrangement under Part 26 of the Companies Act (the “
Scheme”).
for each Scheme Share 210 pence in cash
The terms of the Offer value the entire issued and to be issued ordinary share capital of Scapa at approximately £402.9 million on a fully-diluted basis and represent premia of approximately:
an indirectly wholly-owned subsidiary of Schweitzer-Mauduit International, Inc.
to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006
Summary · The board of directors of AMS Holdco 2 Limited ( SWMBidco ), an indirectly wholly-owned subsidiary of Schweitzer-Mauduit International, Inc. ( SWM ), and the Directors of Scapa Group plc ( Scapa ) are pleased to announce that they have reached agreement on the terms of a recommended cash offer by SWM Bidco for the acquisition of the entire issued and to be issued ordinary share capital of Scapa (the Offer ). The Offer is intended to be effected by means of a scheme of arrangement under Part 26 of the Companies Act (the Scheme ).
SWM
SWM”), and the Directors of Scapa Group plc (“
Scapa”) are pleased to announce that they have reached agreement on the terms of a recommended cash offer by SWM Bidco for the acquisition of the entire issued and to be issued ordinary share capital of Scapa (the “
Offer”). The Offer is intended to be effected by means of a scheme of arrangement under Part 26 of the Companies Act (the “
Scheme”).
for each Scheme Share 210 pence in cash
The terms of the Offer value the entire issued and to be issued ordinary share capital of Scapa at approximately £402.9 million on a fully-diluted basis and represent premia of approximately:
About Synairgen Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta1a broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgen s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people
Synairgen plc: Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
( Synairgen or the Company )
Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
Southampton, UK - 13 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen s inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 patients.
As previously announced, Synairgen has appointed Parexel Biotech, a division of the leading global clinical research organisation, Parexel, to help conduct the Phase III trial and several UK sites have now been initiated, with further sites in the US and the EU expected to follow. The trial is deemed an Urgen